Application of Scaffold-Based Drug Delivery in Oral Cancer Treatment: A Novel Approach
Northern Compound does not answer those questions because they imply personal-use protocols
The side effect profile of any GLP-1 patch would likely reflect both the systemic effects of GLP-1 receptor agonism (common to all delivery methods) and local effects specific to transdermal administration
This leads to multiple metabolic effects, as well as decreasing inflammation and neuroprotective effects.[ref] Two GLP-1 receptor agonists (RAs) currently approved for weight loss are liraglutide and semaglutide
[DOI] [PMC free article] [PubMed] [Google Scholar] 11.Wilding J.P.H., Batterham R.L., Calanna S., Davies M., Van Gaal L.F., Lingvay I., McGowan B.M., Rosenstock J., Tran M.T.D., Wadden T.A., et al